Aging and menopause reprogram osteoclast precursors for aggressive bone resorption

Abstract

Women gradually lose bone from the age of ~35 years, but around menopause, the rate of bone loss escalates due to increasing bone resorption and decreasing bone formation levels, rendering these individuals more prone to developing osteoporosis. The increased osteoclast activity has been linked to a reduced estrogen level and other hormonal changes. However, it is unclear whether intrinsic changes in osteoclast precursors around menopause can also explain the increased osteoclast activity. Therefore, we set up a protocol in which CD14⁺ blood monocytes were isolated from 49 female donors (40–66 years old). Cells were differentiated into osteoclasts, and data on differentiation and resorption activity were collected. Using multiple linear regression analyses combining in vitro and in vivo data, we found the following: (1) age and menopausal status correlate with aggressive osteoclastic bone resorption in vitro; (2) the type I procollagen N-terminal propeptide level in vivo inversely correlates with osteoclast resorption activity in vitro; (3) the protein level of mature cathepsin K in osteoclasts in vitro increases with age and menopause; and (4) the promoter of the gene encoding the dendritic cell-specific transmembrane protein is less methylated with age. We conclude that monocytes are “reprogrammed” in vivo, allowing them to “remember” age, the menopausal status, and the bone formation status in vitro, resulting in more aggressive osteoclasts. Our discovery suggests that this may be mediated through DNA methylation. We suggest that this may have clinical implications and could contribute to understanding individual differences in age- and menopause-induced bone loss.

References

[1] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423:337-342

[2] Katsimbri P. The biology of normal bone remodelling. Eur. J. Cancer Care., 2017, 26

[3] Howard GA, Bottemiller BL, Turner RT, Rader JI, Baylink DJ. Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism. Proc. Natl Acad. Sci., 1981, 78:3204-3208

[4] Parfitt AM, Travers R, Rauch F, Glorieux FH. Structural and cellular changes during bone growth in healthy children. Bone, 2000, 27:487-494

[5] Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev., 2002, 23:279-302

[6] Parfitt AM. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. Invest., 1983, 72:1396-1409

[7] Juliet E, Compston, Michael R, McClung WDL. Osteoporosis. Lancet, 2019, 393:364-376

[8] Chin KY. The relationship between follicle-stimulating hormone and bone health: Alternative explanation for bone loss beyond oestrogen? Int J. Med Sci., 2018, 15:1373-1383

[9] Randolph JF et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: Effect of age at the final menstrual period. J. Clin. Endocrinol. Metab., 2011, 96:746-754

[10] Wang J et al. Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PLoS One, 2015, 10

[11] Riggs BL. The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest., 2000, 106:1203-1204

[12] Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol. Metab., 2012, 23:576-581

[13] Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc. Nutr. Soc., 2008, 67:157-162

[14] Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J. Clin. Endocrinol. Metab., 1995, 80:2447-2450

[15] Eghbali-Fatourechi G et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest., 2003, 111:1221-1230

[16] Cao JJ et al. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J. Bone Min. Res., 2005, 20:1659-1668

[17] Krum SA et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J., 2008, 27:535-545

[18] Mano H et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys. Res Commun., 1996, 223:637-642

[19] Furuyama N, Fujisawa Y. Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts. Steroids, 2000, 65:371-378

[20] Parikka V et al. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology, 2001, 142:5371-5378

[21] Sørensen MG et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J. Bone Min. Metab., 2007, 25:36-45

[22] Henriksen K, Karsdal MA, Taylor A, Tosh D, Coxon FP. Generation of human osteoclasts from peripheral blood. Methods Mol. Biol., 2012, 816:159-175

[23] Marino S, Logan JG, Mellis D, Capulli M. Generation and culture of osteoclasts. Bonekey Rep., 2014, 3:570

[24] Michelsen J et al. Reference intervals for serum concentrations of three bone turnover markers for men and women. Bone, 2013, 57:399-404

[25] Minisola S et al. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos. Int., 2002, 13:171-175

[26] Wang J, Stern PH. Sex-specific effects of estrogen and androgen on gene expression in human monocyte-derived osteoclasts. J. Cell Biochem., 2011, 112:3714-3721

[27] Salamanna F, Giardino R, Fini M. Spontaneous osteoclastogenesis: Hypothesis for gender-unrelated osteoporosis screening and diagnosis. Med Hypotheses, 2017, 109:70-72

[28] Jevon M et al. Gender- and age-related differences in osteoclast formation from circulating precursors. J. Endocrinol., 2002, 172:673-681

[29] Merrild DMH et al. Pit- and trench-forming osteoclasts: A distinction that matters. Bone Res., 2015, 3:15032

[30] Chung PL et al. Effect of age on regulation of human osteoclast differentiation. J. Cell Biochem., 2014, 115:1412-1419

[31] Koshihara Y et al. Osteoclastogenic potential of bone marrow cells increases with age in elderly women with fracture. Mech. Ageing Dev., 2002, 123:1321-1331

[32] Perkins SL, Gibbons R, Kling S, Kahn AJ. Age-related bone loss in mice is associated with an increased osteoclast progenitor pool. Bone, 1994, 15:65-72

[33] Salamanna F et al. In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes. Age (Omaha)., 2015, 37:9819

[34] D’Amelio P et al. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J., 2004, 19:410-412

[35] Zampieri M et al. Reconfiguration of DNA methylation in aging. Mech. Ageing Dev., 2015, 151:60-70

[36] Pal S, Tyler JK. Epigenetics and aging. Sci. Adv., 2016, 2

[37] Levine ME et al. Menopause accelerates biological aging. Proc. Natl Acad. Sci., 2016, 113:9327-9332

[38] Ulrich CM et al. Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. Epigenetics, 2012, 7:1020-1028

[39] Bahl A et al. Hormone replacement therapy associated white blood cell dna methylation and gene expression are associated with within-pair differences of body adiposity and bone mass. Twin Res Hum. Genet., 2015, 18:647-661

[40] Friso S et al. Oestrogen replacement therapy reduces total plasma homocysteine and enhances genomic DNA methylation in postmenopausal women. Br. J. Nutr., 2007, 97:617-621

[41] Morris JA et al. Epigenome-wide association of dna methylation in whole blood with bone mineral density. J. Bone Min. Res., 2017, 32:1644-1650

[42] Ghayor C, Weber FE. Epigenetic regulation of bone remodeling and its impacts in osteoporosis. Int J. Mol. Sci., 2016, 17

[43] Reppe S et al. Distinct DNA methylation profiles in bone and blood of osteoporotic and healthy postmenopausal women. Epigenetics, 2017, 12:674-687

[44] Guo Y et al. Integrating epigenomic elements and GWASs identifies BDNF gene affecting bone mineral density and osteoporotic fracture risk. Sci. Rep., 2016, 6

[45] Søe K, Delaissé JM. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J. Bone Min. Res., 2010, 25:2184-2192

[46] Søe K, Merrild DMH, Delaissé JM. Steering the osteoclast through the demineralization-collagenolysis balance. Bone, 2013, 56:191-198

[47] de la Rica L, Rodríguez-Ubreva J, García M. Islam ABMMK, Urquiza JM, Hernando H, et al. PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation. Genome Biol., 2013, 14

[48] Chiu YH, Ritchlin CT. DC-STAMP: a Key Regulator in Osteoclast Differentiation. J. Cell Physiol., 2016, 231:2402-2407

[49] Courtial N et al. Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMP. FASEB J., 2011, 26:523-532

[50] Saftig P et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl Acad. Sci. Usa., 1998, 95:13453-13458

[51] Gelb BD et al. Cathepsin K: Isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene. Biochem Mol. Med., 1996, 59:200-206

[52] Garnero P et al. the collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem., 1989, 273:32347-32352

[53] Xiao Y et al. Identification of the common origins of osteoclasts, macrophages, and dendritic cells in human hematopoiesis. Stem Cell Rep., 2015, 4:984-994

[54] Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity, 2003, 19:71-82

[55] Arenson EB, Epstein MB, Seeger RC. Volumetric and functional heterogeneity of human monocytes. J. Clin. Invest., 1980, 65:613-618

[56] Seidler S, Zimmermann HW, Bartneck M, Trautwein C, Tacke F. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol., 2010, 11:30

[57] Petitprez V et al. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Int J. Lab Hematol., 2015, 37:29-35

[58] He X et al. Identification and characterization of MicroRNAs by high through-put sequencing in mesenchymal stem cells and bone tissue from mice of age-related osteoporosis. PLoS One, 2013, 8

[59] Noren Hooten N et al. Age-related changes in microRNA levels in serum. Aging (Albany NY)., 2013, 5:725-740

[60] Jevon M et al. Osteoclast formation from circulating precursors in osteoporosis. Scand. J. Rheumatol., 2003, 32:95-100

[61] Mosekilde L. Consequences of the remodelling process for vertebral trabecular bone structure: a scanning electron microscopy study (uncoupling of unloaded structures). Bone Miner., 1990, 10:13-35

[62] Rumpler M et al. Osteoclasts on bone and dentin in vitro: mechanism of trail formation and comparison of resorption behavior. Calcif. Tissue Int., 2013, 93:526-539

[63] Gentzsch C, Delling G, Kaiser E. Microstructural classification of resorption lacunae and perforations in human proximal femora. Calcif. Tissue Int., 2003, 72:698-709

[64] Søe K, Delaissé J-M. Time-lapse reveals that osteoclasts can move across the bone surface while resorbing. J. Cell Sci., 2017, 130:2026-2035

[65] Lotinun S et al. Osteoclast-specifc cathepsin K deletion stimulates S1P-dependent bone formation. J. Clin. Invest., 2013, 123:666-681

[66] Jensen PR, Andersen TL, Pennypacker BL, Duong LT, Delaissé JM. The bone resorption inhibitors Odanacatib and Alendronate affect post-osteoclastic events differently in Ovariectomized rabbits. Calcif. Tissue Int., 2014, 94:212-222

[67] Fuller K et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone, 2008, 42:200-211

[68] Abdelgawad ME et al. Does collagen trigger the recruitment of osteoblasts into vacated bone resorption lacunae during bone remodeling? Bone, 2014, 67:181-188

[69] Panwar P et al. An ectosteric inhibitor of cathepsin k inhibits bone resorption in ovariectomized mice. J. Bone Min. Res., 2017, 32:2415-2430

[70] Xie H et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med., 2014, 20:1270-1278

[71] Leung P, Pickarski M, Zhuo Y, Masarachia PJ, Duong LT. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone, 2011, 49:623-635

[72] Panwar P et al. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K. Br. J. Pharmacol., 2016, 173:396-410

[73] Piper K, Boyde A, Jones SJ. The relationship between the number of nuclei of an osteoclast and its resorptive capability in vitro. Anat. Embryol., 1992, 186:291-299

[74] Møller AMJ, Delaissé JM, Søe K. Osteoclast fusion: time-lapse reveals involvement of CD47 and syncytin-1 at different stages of nuclearity. J. Cell Physiol., 2017, 232:1396-1403

[75] Møller AMJ et al. Septins are critical regulators of osteoclastic bone resorption. Sci. Rep., 2018, 8

[76] Mulari MTK, Qu Q, Härkönen PL, Väänänen HK. Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro. Calcif. Tissue Int., 2004, 75:253-261

[77] Søe K et al. Involvement of human endogenous retroviral syncytin-1 in human osteoclast fusion. Bone, 2011, 48:837-846